Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Res. 2012 Jan 15;72(2):402-7. doi: 10.1158/0008-5472.CAN-11-2464. Epub 2011 Nov 29.

Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.

Author information

  • 1AA. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA 02129, USA. sorensen@nmr.mgh.harvard.edu

Erratum in

  • Cancer Res. 2012 Jan 15;72(2):doi:10.1158/0008-5472.CAN-12-0113.
  • Cancer Res. 2012 Mar 1;72(5):1316.

Abstract

The abnormal vasculature of the tumor microenvironment supports progression and resistance to treatment. Judicious application of antiangiogenic therapy may normalize the structure and function of the tumor vasculature, promoting improved blood perfusion. However, direct clinical evidence is lacking for improvements in blood perfusion after antiangiogenic therapy. In this study, we used MRI to assess tumor blood perfusion in 30 recurrent glioblastoma patients who were undergoing treatment with cediranib, a pan-VEGF receptor tyrosine kinase inhibitor. Tumor blood perfusion increased durably for more than 1 month in 7 of 30 patients, in whom it was associated with longer survival. Together, our findings offer direct clinical evidence in support of the hypothesis that vascular normalization can increase tumor perfusion and help improve patient survival.

PMID:
22127927
[PubMed - indexed for MEDLINE]
PMCID:
PMC3261301
Free PMC Article

Images from this publication.See all images (4)Free text

Figure 1
Figure 2
Figure 3
Figure 4

Publication Types, MeSH Terms, Substances, Secondary Source ID, Grant Support

Publication Types

MeSH Terms

Substances

Secondary Source ID

Grant Support

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk